220
Participants
Start Date
October 31, 2011
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
Ocriplasmin
0.125 mg single intravitreal injection
Sham injection
Sham injection
Retina Vitrous Surgeons of CNY, Syracuse
Mid Atlantic Retina, Huntingdon Valley
Southeast Clinical Research, PA, Charlotte
MedEye Associates, Miami
Center for Retina and Macular Disease, Winter Haven
Retina Associates of Cleveland, Cleveland
Cincinnati Eye Institute, Cincinnati
Associated Retinal Consultants, Royal Oak
Sabates Eye Center Research, Kansas City
Texas Retina Associates, Dallas
Eye Care Associate, Tyler
Texas Retina Associates, Arlington
Retina Consultants, PA, Fort Worth
Vitroretinal Consultants, Houston
Retina Consultants of San Antonio, San Antonio
Valley Retina Institute, P.A., McAllen
Retina Research Center, Austin
Retinal Consultants of Arizona, Phoenix
Retina-Vitreous Associates Medical Group, Beverly Hills
West Coast Retina Group, Inc, San Francisco
Bay Area Retina Associates, Walnut Creek
Retina Consultants Medical Group, Sacramento
Eyesite Opthalmic Services, PA, Portsmouth
Retina-Vitreous Center, PA, New Brunswick
Retina Association of NJ, Teaneck
Lead Sponsor
ThromboGenics
INDUSTRY